	US 11,938,173 B2
	*Use of Clostridium histolyticum* protease mixture in promoting wound healing**
Ira Herman, Boston, MA (US); Vincent Ronfard, Keller, TX (US); and Lei Shi, Mansfield, TX (US)
Assigned to SMITH & NEPHEW, INC., Memphis, TN (US)
Appl. No. 15/534,547
Filed by SMITH & NEPHEW, INC., Memphis, TN (US)
PCT Filed Dec. 10, 2015, PCT No. PCT/US2015/065024 § 371(c)(1), (2) Date Jun. 9, 2017, PCT Pub. No. WO2016/094675, PCT Pub. Date Jun. 16, 2016.
Claims priority of provisional application 62/091,313, filed on Dec. 12, 2014.
Prior Publication US 2017/0360904 A1, Dec. 21, 2017
Int. Cl. A61K 38/48 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/70 (2006.01); A61K 35/74 (2015.01); A61K 45/06 (2006.01)

CPC A61K 38/4886 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/7007 (2013.01); A61K 35/74 (2013.01); A61K 38/48 (2013.01); A61K 45/06 (2013.01); C12Y 304/24003 (2013.01)]

11 Claims

1. A method for inducing proliferation of fibroblasts in a wound in vivo to promote repair of the wound, the method comprising administering a composition comprising a protease mixture comprising collagenases and a neutral protease to the wound in an amount effective for inducing the proliferation of fibroblasts in the wound, wherein the protease mixture is obtained from fermenting Clostridium histolyticum and includes collagenase ColG, collagenase ColH, and non-specific neutral protease, wherein the wound is a diabetic foot ulcer, venous leg ulcer, arterial leg ulcer, decubitus ulcer, stasis ulcer, dermal ulcer, pressure ulcer or a peptic ulcer, wherein the wound is one that has been debrided prior to administration of the composition, and wherein the wound is entirely devoid of necrotic tissue prior to administration of the composition.